AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial
AZR-MD-001 0.5% significantly improved MGD signs and hours of comfortable CL wear, demonstrating good efficacy, safety, and tolerability in those with CLD.
Authors
- Yair Alster
- Charles Bosworth
- Fiona Jane Stapleton (ORCID: https://orcid.org/0000-0002-7203-5443)
- Robin L. Chalmers (ORCID: https://orcid.org/0000-0003-3724-5872)
- Lyndon Jones (ORCID: https://orcid.org/0000-0002-7409-7349)
- Jacqueline Tan (ORCID: https://orcid.org/0000-0003-4986-4945)
- Mark Hinds
Institutions
- UNSW Sydney (AU)
- Cancer Trials Australia (AU)
- Clinical Research Atlanta (US)
Publication Details
- Journal
- The Ocular Surface
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.jtos.2024.12.009
- Citations
- 3
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 1.63